Boston is gaining momentum as a hub for biotechnology research, but San Francisco is not quietly giving up the spot as a top hub, writes Luke Timmerman. San Francisco offers a feeling of expansiveness while Boston packs industry, investors, researchers and hospitals into a tight geographic space, offering a feeling of closeness, says Una Ryan, the former Avant Immunotherapeutics CEO who recently moved from Boston to San Francisco. Though both cities have done much to build their biotech economies, neither can afford to rest, Timmerman notes.

Full Story:

Related Summaries